← Back to Search
Structure-activity Relationship Of Novel And Known Inhibitors Of Human Dimethylarginine Dimethylaminohydrolase-1: Alkenyl-amidines As New Leads.
J. Kotthaus, D. Schade, Nikola Muschick, E. Beitz, B. Clement
Published 2008 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
Recent studies demonstrated that inhibition of dimethylarginine dimethylaminohydrolase (DDAH) activity could be a new strategy to indirectly affect nitric oxide (NO) formation by elevating N(omega)-methylated L-arginine (NMMA, ADMA) levels. This approach is an alternate strategy for the treatment of diseases associated with increased NO-concentrations. To date, three classes of potent inhibitors are known: (1) pentafluorophenyl sulfonates (IC(50)=16-58 microM, PaDDAH), which are also inhibitors for the arginine deiminase; (2) the most potent inhibitors are based on indolylthiobarbituric acid (IC(50)=2-17 microM, PaDDAH), which were identified by virtual modelling; and (3) L-arginine analogs, whose best representative is N(omega)-(2-methoxyethyl)-L-arginine (IC(50)=22 microM, rat DDAH). Based on these known structures, we aimed to develop inhibitors for the human DDAH-1 with improved potency and better relative selectivity for DDAH-1 over NOS. Particularly, the binding pocket of the guanidine-moiety was investigated by screening differently substituted guanidines, amidines and isothioureas in order to collect information on possible binding modes in the active site. All substances were tested in a plate-reader format and HPLC assay and several potent inhibitors were identified with K(i)-values varying from 2 to 36 microM, with N(5)-(1-iminobut-3-enyl)-L-ornithine (L-VNIO) being the most potent inhibitor of the human DDAH-1 so far described. Besides these potent inhibitors alternate substrates for hDDAH-1 were identified as well.
This paper references
Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney.
T. Ogawa (1989)
Structure of the mammalian NOS regulator dimethylarginine dimethylaminohydrolase: A basis for the design of specific inhibitors.
D. Frey (2006)
Potent and selective inhibition of neuronal nitric oxide synthase by N(ω)-propyl-L-arginine
H. Q. Zhang (1997)
Biological significance of endogenous methylarginines that inhibit nitric oxide synthases.
J. Leiper (1999)
A colorimetric 96-well microtiter plate assay for the determination of enzymatically formed citrulline.
M. Knipp (2000)
Cytochrome P450 catalyzes the oxidation of N omega-hydroxy-L-arginine by NADPH and O2 to nitric oxide and citrulline.
J. L. Boucher (1992)
Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond
R. Böger (2006)
Endothelial dysfunction and oxidative stress in arterial hypertension.
P. Ferroni (2006)
NG-allyl- and NG-cyclopropyl-L-arginine: two novel inhibitors of macrophage nitric oxide synthase.
N. M. Olken (1992)
Searching for DDAH inhibitors: S-nitroso-L-homocysteine is a chemical lead.
M. Knipp (2005)
Reduction of Nω-hydroxy-l-arginine to l-arginine by pig liver microsomes, mitochondria, and human liver microsomes
B. Clement (2006)
Disruption of methylarginine metabolism impairs vascular homeostasis
J. Leiper (2007)
REDUCTION OF N-HYDROXYLATED COMPOUNDS: AMIDOXIMES (N-HYDROXYAMIDINES) AS PRO-DRUGS OF AMIDINES
B. Clement (2002)
Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas.
E. Garvey (1994)
Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease
T. Abe (2001)
1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of Inducible Nitric-oxide Synthase in Vitro and in Vivo*
E. Garvey (1997)
Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins.
C. Tran (2000)
Nitric oxide and penile erectile function.
N. Toda (2005)
Discovery of inhibitors of the pentein superfamily protein dimethylarginine dimethylaminohydrolase (DDAH), by virtual screening and hit analysis.
B. Hartzoulakis (2007)
Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in no regulation.
Scott P. Forbes (2008)
Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase.
S. Rossiter (2005)
N5-(1-Imino-3-butenyl)-L-ornithine. A neuronal isoform selective mechanism-based inactivator of nitric oxide synthase.
B. R. Babu (1998)
Nitric-oxide synthase assays.
J. Hevel (1994)
Characterization of a transient covalent adduct formed during dimethylarginine dimethylaminohydrolase catalysis.
E. Stone (2005)
Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine: dimethylargininase and peptidylarginine deiminase.
E. Stone (2005)
N omega-hydroxyl-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase.
J. L. Boucher (1994)
ADVANCES IN PHARMACOLOGY
J. H. Burn (1957)
N-nitro-L-arginine and N-monomethyl-L-arginine exhibit a different pattern of inactivation toward the three nitric oxide synthases.
D. Reif (1995)
Nδ-Methylated l-arginine derivatives and their effects on the nitric oxide generating system
J. Kotthaus (2008)
Structure-function studies on nitric oxide synthases.
H. Li (2005)
Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase
R. Macallister (1996)
Nitric oxide synthases: structure, function and inhibition.
W. K. Alderton (2001)
Does ADMA cause endothelial dysfunction?
J. Cooke (2000)
Structural Characterization and Kinetics of Nitric-oxide Synthase Inhibition by Novel N5-(Iminoalkyl)- and N5-(Iminoalkenyl)-ornithines*
Lynn E. Bretscher (2003)
This paper is referenced by
Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk.
R. Böger (2009)
On the selectivity of neuronal NOS inhibitors
B. Pigott (2013)
Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease.
D. Schade (2010)
Inhibition of Dimethylarginine Dimethylaminohydrolase (DDAH) Enzymes as an Emerging Therapeutic Strategy to Target Angiogenesis and Vasculogenic Mimicry in Cancer
J. Hulin (2019)
Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.
D. Schade (2011)
Amidine-Based Compounds Affecting l-Arginine Metabolism
C. Maccallini (2017)
Characterization of C‐Alkyl Amidines as Bioavailable Covalent Reversible Inhibitors of Human DDAH‐1
M. Lluis (2011)
Arginine analogues incorporating carboxylate bioisosteric functions are micromolar inhibitors of human recombinant DDAH-1.
S. Tommasi (2015)
A Novel and Potent Inhibitor of Dimethylarginine Dimethylaminohydrolase: A Modulator of Cardiovascular Nitric Oxide
Yohannes T. Ghebremariam (2014)
A Continuous, Fluorescent, High-Throughput Assay for Human Dimethylarginine Dimethylaminohydrolase-1
Thomas W. Linsky (2011)
Reduction of N(ω)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC).
J. Kotthaus (2011)
The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis
J. Leiper (2011)
Untersuchung der Umsetzung asymmetrisch methylierter Argininedurch rekombinant hergestellte und native Dimethylarginin-Dimethylaminohydrolase-2
Karin S Altmann (2014)
Structure-based and random mutagenesis approaches increase the organophosphate-degrading activity of a phosphotriesterase homologue from Deinococcus radiodurans.
R. Hawwa (2009)
Arylazoamidoximes and Related Compounds as NO‐modulators
A. Schroeder (2010)
Dimethylarginine‐Dimethylaminohydrolase‐2 (DDAH‐2) Does Not Metabolize Methylarginines
Karin S Altmann (2012)
Development of a Dimethylarginine Dimethylaminohydrolase (DDAH) Assay for High-Throughput Chemical Screening
Yohannes T. Ghebremariam (2012)
Screening for dimethylarginine dimethylaminohydrolase inhibitors reveals ebselen as a bioavailable inactivator.
Thomas W. Linsky (2011)
Efficient access to polysubstituted amidines, benzimidazoles and pyrimidines from amides
J. Wang (2010)
Discovery of structurally-diverse inhibitor scaffolds by high-throughput screening of a fragment library with dimethylarginine dimethylaminohydrolase.
Thomas W. Linsky (2012)
Developing an Irreversible Inhibitor of Human DDAH‐1, an Enzyme Upregulated in Melanoma
Yun Wang (2014)
Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro.
J. Hulin (2019)
Biological activities of guanidine compounds, 2008 – 2012 update
F. Sa̧czewski (2013)
Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and Development
R. B. Murphy (2016)
Designing modulators of dimethylarginine dimethylaminohydrolase (DDAH): A focus on selectivity over arginase
J. Kotthaus (2012)